Kent County Council adult social care 'requires improvement'
Adult social care provision in Kent needs to improve, a watchdog has said.In a report published on Friday, the Care Quality Commission (CQC) also said it found "stark contrasts" and "health inequalities" between inland and coastal communities in Kent.There was a gap in life expectancy of up to eight years between some parts of the county, the body noted.Kent County Council has been approached for comment.
The authority scored two out of four in seven of the nine categories it was judged in, and three out of four in the remaining two.James Bullion, CQC's chief inspector of adult social care and integrated care, said investigators met "enthusiastic and committed staff" but also found "stark contrasts between different areas".He added: "Health inequalities persist despite the authority's efforts to address them."While Kent's health outcomes are often better than the national average, this isn't true for coastal areas where communities face worse health outcomes, poorer quality housing, and seasonal employment."The six-to-eight-year gap in life expectancy between the most and least deprived areas of Kent illustrates these inequalities."But he said the authority was doing "some good work" to reduce inequalities.
The report found KCC did not manage transitions between services well, had an uneven distribution of care home places across the county and up to 600 people in hospital beds who could have been cared for elsewhere.The commission praised the council's efforts to involve people who used services in decision making, and in using new technology, such as an online financial calculator for residents to work out their personal contributions.It said there were "strong foundations" for the future.Political leadership of the council passed from the Conservatives to Reform in May's local elections.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
an hour ago
- Telegraph
Weight-loss jabs can stop HRT working, doctors warn
Weight-loss drugs could stop hormone replacement therapy from working and increase the associated risks, guidance has warned. The British Menopause Society has told doctors to closely monitor any women who are on hormone replacement therapy (HRT) for the menopause and are also taking a weight-loss jab. The injections, such as Mounjaro and Wegovy, also sold as Ozempic for diabetes, have revolutionised obesity treatment and are increasingly taken by people who are not obese but looking to lose a few pounds. But the drug's ability to delay the transit of food through the gut can slow the absorption of pills taken orally. It is one theory behind the so-called ' Ozempic baby boom '. Earlier this week, the medicines regulator issued a warning about the impact of weight-loss drugs on contraception after receiving more than 40 reports relating to pregnancies from women on the jabs. The Medicines and Healthcare products Regulatory Agency said women should 'not rely on oral contraception' and warned them not to use the injections if pregnant or trying to get pregnant because of a lack of safety evidence. Guidance has now suggested women taking HRT orally may also be at risk. There were 2.6 million women taking HRT in 2023-24 in England to help with symptoms of the menopause, which can include hot flushes, night sweats, difficulty sleeping, mood changes, and muscle aches. It typically onsets between age 45 and 55 and can last for a number of years. The most common form of HRT is a progesterone pill alongside a skin patch or gel to deliver oestrogen, although some women will be on a combined pill. The progesterone is important to balance out the effects of oestrogen, which on its own stimulates the growth of the womb lining, and can cause ' abnormal cells and cancer ' to grow. The loss of the protective effect of progesterone on the womb was the primary concern for the British Menopause Society, which recommended doctors move women to an intrauterine device, such as a Mirena coil, or increase the dose of progesterone. Prof Annice Mukherjee, a consultant endocrinologist and member of the society's medical advisory council, who led on the guidance, said an imbalance in the hormones, particularly among women with obesity, would put them 'at increased risk of womb cancer '. 'Oestrogen is almost always given through the skin for HRT in women living with obesity, but progesterone is frequently given as a tablet, and that formulation is thought to be the safest route for women who have complicated health issues,' she said. 'If we then start one of these injectable weight-loss drugs, then you're preferentially stopping absorption of the progestogen that's coming in orally, but you're allowing plenty of the oestrogen through the skin. 'The rules are very clear that if you give a very high dose of oestrogen and you don't give enough progesterone, however that happens, you're putting that woman at risk of womb cancer,' she said. Prof Mukherjee said there was currently a 'culture of putting women on very high doses of oestrogen', which can make the womb lining thicken. 'It's like having a lawn in a woman's womb. Oestrogen makes the lawn grow. Progestogen cuts the lawn. But if it's not being cut, it grows thicker, and then you can get abnormal cells and cancer.' But she also stressed that the biggest risk factor for womb cancer was obesity and so on the whole the weight-loss injections were a positive tool to reduce weight and cancer risk. 'These drugs reduce the risk of cancer,' she said. 'But if they are prescribed to a woman who's on oestrogen through the skin, and she might already have womb thickening because she's living with obesity, and she's not absorbing the progesterone because she's been put on a weight-loss injection, she's potentially getting loads of oestrogen on top of her thickened womb lining, and that could potentially unmask cancers that are there or drive an early cancer to a more advanced stage.' More than 1.5 million people in the UK are now taking weight-loss jabs, with demand doubling in the last six months. The overwhelming majority are accessing them privately from pharmacies at a cost of around £200 per month. It is not known how many people are on both drugs, but the British Menopause Society has created guidelines after calls from GPs for advice to give to patients. Dr Janet Barter, the president of the Faculty of Sexual and Reproductive Healthcare, said there was 'a small but growing body of evidence that the new diabetes and weight loss drugs, which can bring really positive improvements to people's health, can also cause vomiting and severe diarrhoea in some patients'. 'Obviously this could render any medication, such as HRT tablets or oral contraception, ineffective if there hasn't been enough time for them to be fully absorbed,' she said. 'If these side-effects are occurring, then people should discuss the matter with their doctor or specialist clinician to find the combination of drugs that's right for them.'
BBC News
an hour ago
- BBC News
New EMAS ambulances to replace 30 older vehicles
East Midlands Ambulance Service (EMAS) is to replace 30 of its older ambulances across the move is part of a £4.7m government investment in new ambulances in the East Midlands, with the vehicles expected to arrive by next government says it aims to replace almost 500 ageing ambulances across England as part of a £450m plan to reform the NHS and improve emergency Urgent and Emergency Care Plan 2025/26 seeks to reduce pressure on emergency departments as demand for ambulance services nationally has increased. Health Secretary Wes Streeting said: "These 30 new ambulances will make a real difference to patients in the East Midlands, replacing old and tired vehicles and getting to patients in minutes, rather than hours."We can't fix more than a decade of underinvestment and neglect overnight. But through the measures, we will deliver faster and more convenient care for patients in emergencies."EMAS currently has a fleet of 827 operational vehicles, including emergency ambulances, fast response cars, specialised and driver training vehicles, community first responder vehicles and urgent care and patient transport vehicles, according to its annual report.
The Independent
2 hours ago
- The Independent
NHS to get up to £30 billion as other services squeezed in spending review
The NHS is set to be one of the big winners in next week's spending review – with a boost of up to £30 billion at the expense of other public services. The Department for Health and Social Care is set to get the biggest settlement in the government 's spending review next week, while other areas will face cuts. Chancellor Rachel Reeves will argue that Labour is investing in health, security and the economy, according to reports in The Times. The Department of Health is set to be handed a 2.8% annual increase in its day-to-day budget over a three-year period. This amounts to a cash increase of £30 billion by 2028 - £17 billion in real terms. However, the health services capital spending budget will only increase in line with inflation, according to the reports. Reeves will put £113 billion a year extra in infrastructure spending for projects designed to grow the economy, such as the Sizewell C nuclear power plant and a new generation of mini reactors. Bringing down NHS waiting times was one of Labour's key commitments. Sir Keir Starmer has pledged to ensure that by the next election 92% of patients in England waiting for planned treatment are seen within 18 weeks of being referred. Latest NHS data suggests around 60% of people are currently seen in this time and figures released last month showed the overall number of patients on waiting lists had risen slightly from 6.24 million to 6.25 million. Meanwhile, in order to meet tough financial savings targets this year and reduce the NHS its deficit by around £6.5 billion, hospital leaders have warned they're being forced to make cuts to frontline services. The NHS received £3.1 billion in additional capital investment in the 2024 budget, however, health leaders warned this was short of the £6.4 billion a year needed for the NHS to meet its productivity target of 2 per cent a year. A recent analysis by The Nuffield Trust shows that since coming into office, Labour has set healthcare spending to grow at 2.9 per cent for 2024-25 and 2025-26. Between 2011 and 2023-24, budgets grew at 2.4 per cent. For 2025-25, £1.5 billion of the additional funding for the NHS is due to cover the costs of the increase in employer National Insurance contributions, meaning for this financial year, spending growth will actually be less than 2 per cent, the Nuffield Trust estimates. Following the autumn budget, £22.6 billion extra was allocated to the DHSC however, this will be absorbed by spending pressures such as inflation and meeting waiting times targets. Matthew Taylor, chief executive of the NHS Confederation, told The Times that without big changes to the way the health service treats patients, the funding increase 'is not going to enable us to achieve recovery and reform'. 'Without additional capital investment, either traditional or through the private sector, I just don't think it's possible to combine recovery and reform,' he said.
